Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs

The risk of hepatitis C virus (HCV) recurrence after direct-acting antiviral (DAA) treatment is <0.5%. However, the distinction between HCV RNA late relapse and reinfection still represents a challenge in virological diagnostics. The aim of this study was to employ next-generation sequencing (NGS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Viruses
Autors principals: Minosse, Claudia, Gruber, Cesare E. M., Rueca, Martina, Taibi, Chiara, Zaccarelli, Mauro, Grilli, Elisabetta, Montalbano, Marzia, Capobianchi, Maria R., Antinori, Andrea, D’Offizi, Gianpiero, McPhee, Fiona, Garbuglia, Anna Rosa
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8235384/
https://ncbi.nlm.nih.gov/pubmed/34208646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/v13061151
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars